BioLife Solutions Inc

BLFS

18.650USD

-1.000-5.09%

Market hours （ET）Quotes delayed by 15 min

BioLife Solutions Inc's Score

Industry at a Glance

Industry Ranking

20 / 208

Overall Ranking

97 / 4542

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

BioLife Solutions Inc Highlights

StrengthsRisks

BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 26.84% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 96.21M.

Undervalued

The company’s latest PE is -193.20, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 49.86M shares, decreasing 1.47% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 96.29K shares of this stock.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

32.400

Target Price

+64.89%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of BioLife Solutions Inc is 7.70, ranking 58 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 18.79M, representing a year-over-year increase of 64.72%, while its net profit experienced a year-over-year increase of 11.15%.

Score

Industry at a Glance

Previous score

7.70

Change

0



Financials

8.63

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.99

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.46

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.24

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.17

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of BioLife Solutions Inc is 7.43, ranking 87 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -193.20, which is -98.04% below the recent high of -3.78 and -151.84% above the recent low of -486.57.

Score

Industry at a Glance

Previous score

7.43

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 20/208

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of BioLife Solutions Inc is 8.40, ranking 34 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 32.00, with a high of 34.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

8.40

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of BioLife Solutions Inc is 6.78, ranking 63 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 22.38 and the support level at 16.33, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.06

Change

-0.28

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of BioLife Solutions Inc is 10.00, ranking 1 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 109.33%, representing a quarter-over-quarter decrease of 3.02%. The largest institutional shareholder is The Vanguard, holding a total of 3.08M shares, representing 6.38% of shares outstanding, with 8.45% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Casdin Capital, LLC

5.96M

-11.18%

BlackRock Institutional Trust Company, N.A.

5.10M

+0.42%

T. Rowe Price Investment Management, Inc.

4.07M

-4.24%

Invesco Advisers, Inc.

3.48M

+0.62%

The Vanguard Group, Inc.

Star Investors

2.96M

+2.43%

State Street Investment Management (US)

1.46M

+3.38%

Fred Alger Management, LLC

1.11M

-11.15%

Dimensional Fund Advisors, L.P.

1.00M

+2.05%

Fidelity Management & Research Company LLC

1.02M

+35792.97%

MFS Investment Management

1.10M

-0.43%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of BioLife Solutions Inc is 6.45, ranking 60 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.99. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

BioLife Solutions Inc

BLFS

7.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Thermo Fisher Scientific Inc

TMO

8.39 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Bioventus Inc

BVS

8.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Anika Therapeutics Inc

ANIK

8.13 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Lantheus Holdings Inc

LNTH

8.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Edwards Lifesciences Corp

EW

8.05 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment